Martin Samuel Bates 4
4 · Celldex Therapeutics, Inc. · Filed Jan 6, 2026
Insider Transaction Report
Form 4
Martin Samuel Bates
SVP AND CFO
Transactions
- Exercise/Conversion
Common Stock
2026-01-02$10.38/sh+4,817$50,000→ 32,942 total - Exercise/Conversion
Incentive Stock Option (Right to Buy)
2026-01-02−4,817→ 58,815 totalExercise: $10.38Exp: 2030-06-18→ Common Stock (4,817 underlying)
Footnotes (1)
- [F1]As of June 18, 2024, the option is fully vested.